Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

PHASE4CompletedINTERVENTIONAL
Enrollment

441

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

July 2, 2024

Study Completion Date

July 2, 2024

Conditions
MigraineEpisodic MigrainePhonophobiaPhotophobia
Interventions
DRUG

Rimegepant

rimegepant ODT 75mg daily

Trial Locations (19)

11235

SPRI Clinical Trials, LLC, Brooklyn

19114

Clinical Research Philadelphia, LLC, Philadelphia

23454

Tidewater Integrated Medical Research, Virginia Beach

33165

Phoenix Medical Research, LLC, Miami

37421

WR-ClinSearch, LLC, Chattanooga

45242

Velocity Clinical Research, Cincinnati

48104

Michigan Head Pain & Neurological Institute, Ann Arbor

71301

The Headache Clinic, Alexandria

73034

OK Clinical Research, LLC, Edmond

78230

VIP Trails, San Antonio

VIP Trials, San Antonio

85018

Elite Clinical Studies, LLC, Phoenix

90250

Advanced Investigative Medicine, Inc., Hawthorne

91606

Velocity Clinical Research - North Hollywood, North Hollywood

06708

Chase Medical Research, LLC, Waterbury

02131

Boston Clinical Trials, Boston

08816

CVS HealthHub - East Brunswick, East Brunswick

08648

CVS HealthHub - Lawrenceville, Lawrenceville

08078

CVS HealthHUB - Runnemede, Runnemede

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY